---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000044"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:17:22.731398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase

## Summary
- GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.
- Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.
- Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.
- Board authorizes $150M share repurchase program through Dec 2026.
- FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%.

## SEC filing metadata
- accession: 0001396814-24-000044
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/0001396814-24-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/pcrx-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000044
- JSON: https://secwatch.observer/filing/0001396814-24-000044.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000044.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported first quarter ended March 31, 2024 results: revenue $167.1 million, net income $9.0 million, EPS $0.19 per share (basic and diluted).
  - Period: first quarter ended March 31, 2024
  - Revenue: $167.1 million
  - Net income: $9.0 million
  - EPS: $0.19 per share (basic and diluted)
  - Result: reported results
  source text: First Quarter 2024 Financial Highlights • Total revenues of $167.1 million • Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° • Net income of $9.0 million, or $0.19 per share (basic and diluted)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/0001396814-24-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.